AR129012A1 - Derivados de piridazina fusionados - Google Patents

Derivados de piridazina fusionados

Info

Publication number
AR129012A1
AR129012A1 ARP230100862A ARP230100862A AR129012A1 AR 129012 A1 AR129012 A1 AR 129012A1 AR P230100862 A ARP230100862 A AR P230100862A AR P230100862 A ARP230100862 A AR P230100862A AR 129012 A1 AR129012 A1 AR 129012A1
Authority
AR
Argentina
Prior art keywords
pyridazine derivatives
fused pyridazine
formula
compounds
fused
Prior art date
Application number
ARP230100862A
Other languages
English (en)
Spanish (es)
Inventor
Mark E Adams
Jason W Brown
Edcon Chang
Mingnam Tang
Holger Monenschein
Kristin Schleicher
Huikai Sun
Feng Zhou
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of AR129012A1 publication Critical patent/AR129012A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ARP230100862A 2022-04-07 2023-04-05 Derivados de piridazina fusionados AR129012A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202263328709P 2022-04-07 2022-04-07

Publications (1)

Publication Number Publication Date
AR129012A1 true AR129012A1 (es) 2024-07-03

Family

ID=86329425

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP230100862A AR129012A1 (es) 2022-04-07 2023-04-05 Derivados de piridazina fusionados

Country Status (6)

Country Link
US (1) US20250340563A1 (cg-RX-API-DMAC7.html)
EP (1) EP4504733A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025511819A (cg-RX-API-DMAC7.html)
AR (1) AR129012A1 (cg-RX-API-DMAC7.html)
TW (1) TW202345838A (cg-RX-API-DMAC7.html)
WO (1) WO2023194964A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11618751B1 (en) 2022-03-25 2023-04-04 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives
US11319319B1 (en) 2021-04-07 2022-05-03 Ventus Therapeutics U.S., Inc. Compounds for inhibiting NLRP3 and uses thereof
CA3226995A1 (en) * 2021-07-21 2023-01-26 Nico Therapeutics, Inc. Annulated pyridazine compound
US12331048B2 (en) 2022-10-31 2025-06-17 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors
TW202545527A (zh) 2024-01-16 2025-12-01 英商諾得瑟拉公司 Nlrp3及glp-1a組合療法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
AR119731A1 (es) * 2019-05-17 2022-01-05 Novartis Ag Inhibidores del inflamasoma nlrp3
TW202231281A (zh) * 2020-12-25 2022-08-16 大陸商上海拓界生物醫藥科技有限公司 一類含噠嗪的化合物及其醫藥用途
CA3226995A1 (en) * 2021-07-21 2023-01-26 Nico Therapeutics, Inc. Annulated pyridazine compound

Also Published As

Publication number Publication date
JP2025511819A (ja) 2025-04-16
TW202345838A (zh) 2023-12-01
EP4504733A1 (en) 2025-02-12
WO2023194964A1 (en) 2023-10-12
US20250340563A1 (en) 2025-11-06

Similar Documents

Publication Publication Date Title
CO2022004684A2 (es) Derivados de piridazin-3(2h)-ona fusionados con azol
MX2021013135A (es) Derivados de 1,1-dioxido de 3-amino-4h-benzo[e][1,2,4] tiadiazina como inhibidores de mrgx2.
DOP2024000275A (es) Compuestos de pirido[4,3-d]pirimidina
AR127050A1 (es) Compuestos espirocíclicos
AR119910A1 (es) DERIVADOS DE 4,4a,5,7,8,8a-HEXAHIDROPIRIDO[4,3-b][1,4]OXAZIN-3-ONA COMO INHIBIDORES DE MAGL
AR123018A1 (es) Formulaciones del esteroide c21-n-pirazolilo 19-nor c3,3-disustituido y métodos de uso de este
AR030959A1 (es) Derivados de aminoalcoholes, procedimiento para prepararlos, el uso de los mismos para preparar medicamentos y las composiciones farmaceuticas que las contienen
AR114421A1 (es) Piperidinil-3-(ariloxi)-propanamidas y propanoatos
AR096846A1 (es) Dihidroquinoxalinonas y dihidropiridopirazinonas modificadas como inhibidores de la proteína bet
CL2022003067A1 (es) Derivados de n-(piperidin-4-il)benzamida de acción luminal
ECSP22082217A (es) Derivados de n-heteroarilalquil-2-(heterociclil y heterociclilmetil)acetamida
AR036094A1 (es) Compuestos derivados de acido sulfonico, composicion farmaceutica y su uso en la preparacion de medicamentos
CL2025002805A1 (es) Derivados de amida para inhibir nlrp3 y usos de estos.
CL2025000529A1 (es) Compuestos derivados de dioxoisoquinolinona, inhibidores de ezh1 y/o ezh2; uso para tratar cáncer.
AR131705A1 (es) Derivados de 1-amino-4-fenilftalazina
CO2021017202A2 (es) Compuestos tricíclicos
AR123977A1 (es) 1h-pirazolo[4,3-c]piridinas sustituidas y derivados como inhibidores de egfr
CO2024017138A2 (es) Compuestos amido heteroaromáticos útiles en el tratamiento de enfermedades hepáticas
CL2024002101A1 (es) Proceso de elaboración de derivados de morfolinas sustituidas
DOP2025000013A (es) Inhibidores de inflamasoma nlrp3
CO2025010159A2 (es) Derivados de 3-(2-(dimetilamino)etil)-1h-indol-4-ilo
AR125397A1 (es) Modified ferroportin inhibitors
AR129605A1 (es) PÉPTIDOS CÍCLICOS PARA ATRAPAR INTERLEUCINA-1b
CO2026004514A2 (es) Derivados tricíclicos y usos relacionados
AR132037A1 (es) Derivados de piridazinil amino como inhibidores del receptor alk5

Legal Events

Date Code Title Description
FB Suspension of granting procedure